Jérôme Fayette - Concepedia

Author

Jérôme Fayette

Also Known As

Agustin Horacio Falco, Fayette J, Fayette, Jerôme, Fayette, Jérome, Flor, Maria Jose, J FAYETTE, J Fayette, J. Fayette, J??r??me Fayette, Jerome Fayette

387

Publications

25.6K

Citations

H-Index

Concepts

All Affiliations

Centre Léon Bérard Institut Gustave Roussy Centre Antoine Lacassagne Université Claude Bernard Lyon 1 Fondazione IRCCS Istituto Nazionale dei Tumori

About

Jérôme Fayette is an author at Centre Léon Bérard specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	75	5.3K
2	Health Sciences	22	37	2.2K
3	Cell Biology	5	5	325
4	Public Health	1	1	124
5	Allergy	1	1	235

Jérôme Fayette

125

Publications

24.4K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer H. Borghaei, L. Paz-Ares, Leora Horn, New England Journal of Medicine	2015	9.3K
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, New England Journal of Medicine	2016	4.9K
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) Leora Horn, David R. Spigel, Everett E. Vokes, Journal of Clinical Oncology	2017	857
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, Oral Oncology Neoadjuvant TherapyCheckmate 141MedicineTumor Pd-l1 ExpressionPathology	2018	776
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma Esma Saâda-Bouzid, Cécile Defaucheux, Andy Karabajakian, Annals of Oncology OncologyNeoadjuvant TherapyAnti-pd-1/pd-l1 TherapyImmune Checkpoint InhibitorHead And Neck Cancer	2017	596
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial Kevin J. Harrington, Robert L. Ferris, George R. Blumenschein, The Lancet Oncology OncologyNeoadjuvant TherapyCheckmate 141Cancer ManagementClinical Trials	2017	417
Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases Jérôme Fayette, É. Martin, Sophie Piperno‐Neumann, Annals of Oncology Primary SiteRetrospective StudySurgical PathologyPathologySpecific Behavior	2007	391
Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group Jean‐Yves Blay, Axel Le Cesne, Isabelle Ray‐Coquard, Journal of Clinical Oncology	2007	390
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial Jean-Pascal H. Machiels, Robert I. Haddad, Jérôme Fayette, The Lancet Oncology Neoadjuvant TherapyNeck 1Randomised Phase 3MedicineHead And Neck Cancer	2015	386
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study Robert L. Ferris, Robert I. Haddad, Caroline Even, Annals of Oncology	2020	358

Page 1